$0.37
+0.01 (+3.00%)
Open$0.35
Previous Close$0.36
Day High$0.38
Day Low$0.33
52W High$19.74
52W Low$0.21
Volume—
Avg Volume13.85M
Market Cap10.53M
P/E Ratio—
EPS$-7.39
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+5,809.1% upside
Current
$0.37
$0.37
Target
$22.10
$22.10
$15.13
$22.10 avg
$31.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.51M | 1.76M | 1.31M |
| Net Income | -239,077,261 | -251,778,065 | -292,011 |
| Profit Margin | -15,861.4% | -15,068.3% | -22.2% |
| EBITDA | -199,151,575 | -221,383,098 | -341,169 |
| Free Cash Flow | — | — | -173,511 |
| Rev Growth | -14.5% | -14.5% | +20.5% |
| Debt/Equity | — | — | 0.83 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |